Ionis Pharmaceuticals Inc
NASDAQ:IONS

Watchlist Manager
Ionis Pharmaceuticals Inc Logo
Ionis Pharmaceuticals Inc
NASDAQ:IONS
Watchlist
Price: 34.01 USD 0.21% Market Closed
Market Cap: 5.4B USD
Have any thoughts about
Ionis Pharmaceuticals Inc?
Write Note

Intrinsic Value

IONS's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one IONS stock under the Base Case scenario is 40.4 USD. Compared to the current market price of 34.01 USD, Ionis Pharmaceuticals Inc is Undervalued by 16%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

IONS Intrinsic Value
40.4 USD
Undervaluation 16%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Ionis Pharmaceuticals Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for IONS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about IONS?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Ionis Pharmaceuticals Inc

Provide an overview of the primary business activities
of Ionis Pharmaceuticals Inc.

What unique competitive advantages
does Ionis Pharmaceuticals Inc hold over its rivals?

What risks and challenges
does Ionis Pharmaceuticals Inc face in the near future?

Has there been any significant insider trading activity
in Ionis Pharmaceuticals Inc recently?

Summarize the latest earnings call
of Ionis Pharmaceuticals Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Ionis Pharmaceuticals Inc.

Provide P/S
for Ionis Pharmaceuticals Inc.

Provide P/E
for Ionis Pharmaceuticals Inc.

Provide P/OCF
for Ionis Pharmaceuticals Inc.

Provide P/FCFE
for Ionis Pharmaceuticals Inc.

Provide P/B
for Ionis Pharmaceuticals Inc.

Provide EV/S
for Ionis Pharmaceuticals Inc.

Provide EV/GP
for Ionis Pharmaceuticals Inc.

Provide EV/EBITDA
for Ionis Pharmaceuticals Inc.

Provide EV/EBIT
for Ionis Pharmaceuticals Inc.

Provide EV/OCF
for Ionis Pharmaceuticals Inc.

Provide EV/FCFF
for Ionis Pharmaceuticals Inc.

Provide EV/IC
for Ionis Pharmaceuticals Inc.

Show me price targets
for Ionis Pharmaceuticals Inc made by professional analysts.

What are the Revenue projections
for Ionis Pharmaceuticals Inc?

How accurate were the past Revenue estimates
for Ionis Pharmaceuticals Inc?

What are the Net Income projections
for Ionis Pharmaceuticals Inc?

How accurate were the past Net Income estimates
for Ionis Pharmaceuticals Inc?

What are the EPS projections
for Ionis Pharmaceuticals Inc?

How accurate were the past EPS estimates
for Ionis Pharmaceuticals Inc?

What are the EBIT projections
for Ionis Pharmaceuticals Inc?

How accurate were the past EBIT estimates
for Ionis Pharmaceuticals Inc?

Compare the revenue forecasts
for Ionis Pharmaceuticals Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Ionis Pharmaceuticals Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Ionis Pharmaceuticals Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Ionis Pharmaceuticals Inc compared to its peers.

Compare the P/E ratios
of Ionis Pharmaceuticals Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Ionis Pharmaceuticals Inc with its peers.

Analyze the financial leverage
of Ionis Pharmaceuticals Inc compared to its main competitors.

Show all profitability ratios
for Ionis Pharmaceuticals Inc.

Provide ROE
for Ionis Pharmaceuticals Inc.

Provide ROA
for Ionis Pharmaceuticals Inc.

Provide ROIC
for Ionis Pharmaceuticals Inc.

Provide ROCE
for Ionis Pharmaceuticals Inc.

Provide Gross Margin
for Ionis Pharmaceuticals Inc.

Provide Operating Margin
for Ionis Pharmaceuticals Inc.

Provide Net Margin
for Ionis Pharmaceuticals Inc.

Provide FCF Margin
for Ionis Pharmaceuticals Inc.

Show all solvency ratios
for Ionis Pharmaceuticals Inc.

Provide D/E Ratio
for Ionis Pharmaceuticals Inc.

Provide D/A Ratio
for Ionis Pharmaceuticals Inc.

Provide Interest Coverage Ratio
for Ionis Pharmaceuticals Inc.

Provide Altman Z-Score Ratio
for Ionis Pharmaceuticals Inc.

Provide Quick Ratio
for Ionis Pharmaceuticals Inc.

Provide Current Ratio
for Ionis Pharmaceuticals Inc.

Provide Cash Ratio
for Ionis Pharmaceuticals Inc.

What is the historical Revenue growth
over the last 5 years for Ionis Pharmaceuticals Inc?

What is the historical Net Income growth
over the last 5 years for Ionis Pharmaceuticals Inc?

What is the current Free Cash Flow
of Ionis Pharmaceuticals Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Ionis Pharmaceuticals Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Ionis Pharmaceuticals Inc

Current Assets 2.7B
Cash & Short-Term Investments 4.6B
Receivables 17.9m
Other Current Assets -1.9B
Non-Current Assets 367.2m
PP&E 246.9m
Other Non-Current Assets 120.3m
Current Liabilities 304.6m
Accounts Payable 9.1m
Accrued Liabilities 165m
Other Current Liabilities 130.6m
Non-Current Liabilities 2.1B
Long-Term Debt 1.2B
Other Non-Current Liabilities 880.3m
Efficiency

Earnings Waterfall
Ionis Pharmaceuticals Inc

Revenue
803.1m USD
Cost of Revenue
-10.4m USD
Gross Profit
792.6m USD
Operating Expenses
-1.2B USD
Operating Income
-370.4m USD
Other Expenses
11.6m USD
Net Income
-358.8m USD

Free Cash Flow Analysis
Ionis Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Ionis Pharmaceuticals reported $134 million in Q3 revenue, a 7% decrease year-over-year, but an overall increase of 3% for nine months. The company expects 2024 revenue to exceed $575 million, driven by new launches, including olezarsen for FCS and donidalorsen for HAE. Olezarsen's FDA approval is anticipated on December 19, 2024, targeting a rare patient population. Meanwhile, WAINUA sales grew 44% sequentially. With ongoing investments and a recent $30 million milestone from AstraZeneca for WAINUA's U.K. approval, Ionis aims for sustainable growth and increased value for shareholders.

What is Earnings Call?
Fundamental Scores

IONS Profitability Score
Profitability Due Diligence

Ionis Pharmaceuticals Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional ROIC
ROIC is Increasing
Exceptional 1-Year Revenue Growth
32/100
Profitability
Score

Ionis Pharmaceuticals Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

IONS Solvency Score
Solvency Due Diligence

Ionis Pharmaceuticals Inc's solvency score is 41/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Long-Term Solvency
Average D/E
41/100
Solvency
Score

Ionis Pharmaceuticals Inc's solvency score is 41/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

IONS Price Targets Summary
Ionis Pharmaceuticals Inc

Wall Street analysts forecast IONS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IONS is 61.92 USD with a low forecast of 37.37 USD and a high forecast of 80.85 USD.

Lowest
Price Target
37.37 USD
10% Upside
Average
Price Target
61.92 USD
82% Upside
Highest
Price Target
80.85 USD
138% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for IONS?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for IONS is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

IONS Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Ionis Pharmaceuticals Inc Logo
Ionis Pharmaceuticals Inc

Country

United States of America

Industry

Biotechnology

Market Cap

5.4B USD

Dividend Yield

0%

Description

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company is headquartered in Carlsbad, California and currently employs 660 full-time employees. The firm is primarily focused on our cardiovascular and neurology franchises. Its products include SPINRAZA, TEGSEDI and WAYLIVRA. SPINRAZA is for the treatment of patients of all ages with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. TEGSEDI is for the treatment of patients with polyneuropathy caused by hereditary transthyretin (TTR), amyloidosis (hATTR), a debilitating, progressive, and fatal disease. WAYLIVRA is an antisense medicine indicated as an adjunct to diet in adult patients. The firm has over six medicines in Phase III studies for eight indications, which include Eplontersen (TTR), Olezarsen (ApoC-III), Donidalorsen (PKK), ION363 (FUS), Pelacarsen (Apo(a)) and Tofersen (SOD1). Its cardiovascular medicine in development includes Eplontersen, Olezarsen, Pelacarsen, ION449 (PCSK9), Fesomersen and IONIS-AGT-LRx.

Contact

CALIFORNIA
Carlsbad
2855 Gazelle Ct
+17609319200.0
www.ionispharma.com

IPO

1991-05-17

Employees

660

Officers

Founder, CEO & Director
Dr. Brett P. Monia Ph.D.
Executive VP of Finance & CFO
Ms. Elizabeth L. Hougen M.A., M.B.A., M.S.
Director
Ms. B. Lynne Parshall Esq., J.D.
Executive VP & Chief Development Officer
Dr. Richard S. Geary Ph.D.
Executive Vice President of Research
Dr. Eric E. Swayze Ph.D.
Chief Accounting Officer & Senior VP
Mr. Darren Gonzales
Show More
Executive VP & Chief Scientific Officer
Dr. C. Frank Bennett BSc, Ph.D.
Senior Vice President of Investor Relations
Mr. D. Wade Walke Ph.D.
Executive VP, Chief Legal Officer, General Counsel & Corporate Secretary
Mr. Patrick R. O'Neil Esq.
Vice President of Corporate Communications
Ms. Hayley Soffer
Show Less

See Also

Discover More
What is the Intrinsic Value of one IONS stock?

The intrinsic value of one IONS stock under the Base Case scenario is 40.4 USD.

Is IONS stock undervalued or overvalued?

Compared to the current market price of 34.01 USD, Ionis Pharmaceuticals Inc is Undervalued by 16%.

Back to Top